The therapeutic landscapes in HER2+ BC and ER+ BC are evolving rapidly, with a wealth of potential new treatment options that may provide optimal blockade of the HER2 and ER oncogenic drivers within HER2+, ER+ disease. The gene discussed is ESR1; the disease is breast cancer.